Roivant Brepocitinib Expansion, Immunovant Batoclimab Failure
Analysis based on 16 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026
The market impact is mixed for Roivant Sciences. While the expansion of brepocitinib into lichen planopilaris is a positive development, the failure of Immunovant's batoclimab Phase 3 studies in thyroid eye disease is a significant setback, likely leading to a negative short-term reaction for Roivant Sciences and Immunovant shares. HanAll Biopharma, as a partner, will also be negatively affected.
Roivant Sciences announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a severe inflammatory scalp disorder with no FDA-approved therapies. This expands Priovant Therapeutics' late-stage development program for brepocitinib. Concurrently, Immunovant reported that its two Phase 3 clinical studies for batoclimab in thyroid eye disease (TED) failed to meet their primary endpoint, although safety results were consistent with previous findings. Immunovant will review future plans for batoclimab with its partner HanAll Biopharma. Roivant Sciences will host an investor call to discuss these updates.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard